Impact Therapeutics is a privately held clinical-stage biopharmaceutical company incorporated in Nanjing, China, dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. We have assembled most comprehensive global DNA damage response (DDR) pipeline of novel drug candidates generated by in-house discovery platform. We are now expanding drug discovery platform to other novel synthetic lethality targets. Impact has made tremendous progress in several drug discovery projects, including PARP inhibitor, Wee1 inhibitor, other novel DDR agents and Hedgehog pathway inhibitor. The lead program PARP inhibitor IMP4297 is ready for Phase 3 study in China. Preliminary clinical data demonstrated better safety profile and wider therapeutic window. Wee1 inhibitor IMP7068 is undergoing IND enabling studies.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):